Search results
Showing 8611 to 8625 of 8905 results
NICE approves first immunotherapy combination for endometrial cancer
Around 2,100 people with advanced womb cancer are set to benefit from a groundbreaking new treatment option, following our recommendation of pembrolizumab (Keytruda) in final draft guidance published today.
After four years of transformational leadership, NICE CEO Dr Sam Roberts will step down at the end of the year to support her children through a difficult time.
The benefits from donanemab (also called Kisunla and made by Eli Lilly) and lecanemab (also called Leqembi and made by Eisai) - remain too small to justify the additional cost to the NHS, one of our independent committees has concluded following consultation.
Some people with cystic fibrosis are set to benefit from a new once-daily triple therapy treatment, following NICE's recommendation of Alyftrek in final draft guidance published today.
How NICE International is supporting evidence-based decision-making through the Regulatory Partnership for Growth Fund
Thousands could benefit from first immunotherapy for severe birch tree pollen allergy
We have recommended the first under-the-tongue tablet immunotherapy shown to build long-term tolerance to allergens, which could help up to 27,000 people in England with moderate to severe birch tree pollen allergies.
NICE provisionally recommends leadless implantable pacemaker in draft guidance
A procedure for people with slow heart rhythms could be used more widely after it was recommended for NHS use in draft guidance.
Thousands more breast cancer patients to benefit from new NHS treatment
NICE approves ribociclib combination therapy to help prevent cancer returning in early-stage disease.
Home News Podcasts NICE's prioritisation board: focus on what matters most Podcasts 27 June 2025 Listen About this episode In this episode
Four AI technologies conditionally recommended to help detect undiagnosed fragility fractures
The technologies could help healthcare professionals spot hidden spinal fractures in patients undergoing routine CT scans.
NICE responds to publication of the government's Life Sciences Sector Plan
We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing healthtech, while supporting a thriving life sciences industry in the UK.
The innovative hybrid closed loop (HCL) systems offer improved blood sugar control and can transform daily life for families managing this complex condition.
NICE leads the way in approving breakthrough treatment for multiple myeloma
People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.
Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.
Learn more about our updated maternal and child nutrition guideline
Home News Podcasts Learn more about our updated maternal and child nutrition guideline Podcasts 30 May 2025 Listen About this episode We're